Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Drop in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 6,200 shares, a decline of 13.9% from the February 13th total of 7,200 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 164,300 shares, the days-to-cover ratio is currently 0.0 days.

Bioxytran Stock Performance

Shares of BIXT opened at $0.17 on Thursday. The stock has a fifty day moving average price of $0.10 and a two-hundred day moving average price of $0.10. Bioxytran has a 52-week low of $0.06 and a 52-week high of $0.21. The company has a market cap of $14.84 million, a price-to-earnings ratio of -16.84 and a beta of 2.00.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.